Commit To Buy Intellia Therapeutics At $10, Earn 28.5% Using Options

Selling the January 2027 $10 strike put on Intellia Therapeutics (NTLA) is highlighted for its 19.2% annualized return, though it entails the risk of acquiring shares at a $7.15 cost basis if NTLA declines 25.2% from its current $13.21 price, compounded by the stock's high 81% trailing volatility. This specific options opportunity emerges as the broader S&P 500 put:call ratio registers an unusually high 0.80, signaling increased market-wide put buying activity compared to the long-term median of 0.65.

Analysis

The analysis focuses on a specific options strategy for Intellia Therapeutics (NTLA): selling a January 2027 put option with a $10 strike price. This strategy generates a notable 19.2% annualized return from the premium collected. However, it is a high-risk proposition, primarily due to NTLA's extremely high trailing twelve-month volatility of 81%. The trade structure means the put seller only realizes a gain from the premium unless the stock price declines by more than 25.2% from its current $13.21 level, at which point they face assignment and would acquire the shares at an effective cost basis of $7.15. This strategy explicitly forgoes any upside participation in NTLA's potential stock appreciation. The article provides this technical analysis within the context of a broader market exhibiting unusually high put-buying activity, evidenced by an S&P 500 put:call ratio of 0.80, well above the long-term median of 0.65. This suggests heightened bearish sentiment or hedging in the market, which could increase the risk for a high-volatility stock like NTLA. The analysis is purely technical and lacks any fundamental assessment of Intellia's business.

Key Decisions for Investors

• Consider this put-selling strategy primarily for high-yield income generation, suitable only for those willing to acquire Intellia Therapeutics shares at a significant discount and who have conducted separate fundamental analysis to justify the $7.15 effective purchase price.
• The central risk factor is the stock's 81% trailing volatility; while this generates the attractive 19.2% annualized return, it also signals a substantial probability of large price swings that could lead to assignment.
• Investors should note the elevated put buying in the broader market, as a cautious or bearish environment could be a headwind for high-beta biotech stocks and increase the risk of this long-dated options trade.
• This strategy is inappropriate for investors seeking capital appreciation from NTLA, as the position's primary gain is limited to the option premium collected unless the stock falls significantly.